KRAS and neoplasm: Recent investigations have found TCRs targeting the 9-mer KRAS-G12V mutant neoantigen in the context of human leukocyte antigen (HLA-A*11:01), exhibiting effective cytokine production, cytotoxic activity, and anti-tumor potency in preclinical settings.